Loading clinical trials...
Loading clinical trials...
An Open-Label Pilot Study to Evaluate the Safety and Efficacy of DVX201 NK Cells in Patients With Relapsed or Refractory AML or High Risk MDS or High Risk Overlapping Myelodysplastic / Myeloproliferative Neoplasms
Conditions
Interventions
DVX201
Locations
1
United States
Duke University Hospital
Durham, North Carolina, United States
Start Date
December 15, 2021
Primary Completion Date
October 15, 2023
Completion Date
June 4, 2024
Last Updated
July 19, 2024
NCT03520647
NCT06859424
NCT04645199
NCT03050268
NCT05143996
NCT04187105
Lead Sponsor
Coeptis Therapeutics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions